Gideon Blumenthal was named vice president for Global Oncology Regulatory Affairs at Merck.
He is a former deputy director of the FDA Oncology Center of Excellence.
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
